Episode Details

OKYO Pharma’s CEO Robert Dempsey joined Steve Darling from Proactive to announce the appointment of Dr. Marta Sacchetti, MD, PhD, as the newest member of the company’s Scientific Advisory Board (SAB), a move designed to further strengthen the company’s scientific and clinical expertise as it advances its lead ophthalmic programs. Dempsey explained that Sacchetti’s addition enhances OKYO Pharma’s already distinguished global network of scientific and medical advisors. Widely recognized for her expertise in neuro-inflammatory corneal diseases, Sacchetti brings deep knowledge and extensive research experience that aligns with the company’s mission to address significant unmet needs in ophthalmology and ocular surface disease treatment. Sacchetti currently serves as an Associate Professor of Ophthalmology at Link University in Rome, Italy, and has built a strong reputation through her work spanning clinical practice, research, and industry collaboration. Her previous experience as Global Head of Clinical Development, Ophthalmology & Neurotrophins at Dompé Farmaceutici adds another important dimension to her expertise, particularly in areas involving targeted nerve regeneration, pain signaling modulation, and advanced diagnostic approaches. Her research efforts have focused heavily on degenerative, allergic, and neuroimmune diseases affecting the cornea and ocular surface. In addition to her clinical contributions, Sacchetti has authored numerous peer-reviewed scientific publications and presented her findings at leading national and international conferences, reinforcing her standing within the global ophthalmology community. Dempsey noted that her appointment comes at an important stage for OKYO Pharma as the company advances its investigational treatment pipeline. The company’s lead product candidate, Urcosimod, continues to gain attention as the first investigational therapy to receive an Investigational New Drug (IND) designation specifically for the treatment of neuropathic corneal pain. The program has also been granted Fast Track designation by the U.S. Food and Drug Administration, potentially accelerating its path through development and regulatory review. The appointment reflects OKYO Pharma’s ongoing strategy of adding specialized expertise to support the development and commercialization of novel therapies aimed at addressing challenging ophthalmic conditions. #proactiveinvestors #okyopharmalimited #nasdaq #okyo #Urcosimod #NeuropathicCornealPain #HealthcareInnovation #ClinicalDevelopment #NeuroInflammation #CornealDisease #Pharmaceuticals #MedTech #DrugDevelopment #MartaSacchetti